Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Affiliations

• ¹ Beth Israel Deaconess Medical Center, Boston, MA, USA. dmcdermo@bidmc.harvard.edu.
• ² Genentech, Inc., South San Francisco, CA, USA.
• ³ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
• ⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁵ Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
• ⁶ Gustave Roussy, Villejuif, France.
• ⁷ University of California, San Francisco School of Medicine, San Francisco, CA, USA.
• ⁸ Mayo Clinic Hospital -Florida, Jacksonville, FL, USA.
• ⁹ City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
• ¹⁰ Florida Cancer Specialists, Fort Myers, FL, USA.
• ¹¹ Yale School of Medicine, New Haven, CT, USA.
• ¹² Sarah Cannon Research Institute, Nashville, TN, USA.
• ¹³ Vanderbilt University Medical Center, Nashville, TN, USA.
• ¹⁴ University of Chicago Medicine, Chicago, IL, USA.
• ¹⁵ Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
• ¹⁶ Royal Marsden Hospital, London, UK.
• ¹⁷ CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France.
• ¹⁸ Ospedale San Donato, Azienda USL Toscana Sudest, Arezzo, Italy.
• ¹⁹ Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
• ²⁰ Azienda Ospedaliera Universitaria Senese, Center for Immune-Oncology, Siena, Italy.
• ²¹ Medizinische Hochschule, Zentrum Innere Medizin, Abt. Hämatologie u. Onkologie, Hannover, Germany.
• ²² Dana-Farber Cancer Institute, Boston, MA, USA.
• ²³ Roche Products Ltd, Welwyn Garden City, UK.
• ²⁴ Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.